Fabienne Tschanz
Overview
Explore the profile of Fabienne Tschanz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
36
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kirschner M, Meerang M, Orlowski V, Furrer K, Tschanz F, Grgic I, et al.
JTCVS Open
. 2025 Jan;
22():491-503.
PMID: 39780777
Objective: To test the safety and efficacy of combination treatment for pleural mesothelioma (PM) with intracavitary cisplatin-fibrin (cis-fib) plus hemithoracic irradiation (IR) applied after lung-sparing surgery in an orthotopic immunocompetent...
2.
Waller V, Tschanz F, Winkler R, Pruschy M
Front Oncol
. 2023 Mar;
13:1117326.
PMID: 36998455
Purpose: Ionizing radiation (IR) enhances the migratory capacity of cancer cells. Here we investigate in non-small-cell-lung-cancer (NSCLC) cells a novel link between IR-enhanced ADAM17 activity and the non-canonical pathway of...
3.
Tschanz F, Bender S, Telarovic I, Waller V, Speck R, Pruschy M
Cancer Res Commun
. 2023 Mar;
1(3):164-177.
PMID: 36860547
Significance: The tumor response to radiotherapy is influenced by several factors of the tumor microenvironment. We demonstrate that inhibition of the sheddase ADAM17 by the novel antibody MEDI3622 reduces IR-induced...
4.
La Greca Saint-Esteven A, Vuong D, Tschanz F, van Timmeren J, Dal Bello R, Waller V, et al.
Cancers (Basel)
. 2021 Jul;
13(12).
PMID: 34208595
Radiomics supposes an alternative non-invasive tumor characterization tool, which has experienced increased interest with the advent of more powerful computers and more sophisticated machine learning algorithms. Nonetheless, the incorporation of...
5.
Kazimova T, Tschanz F, Sharma A, Telarovic I, Wachtel M, Pedot G, et al.
Mol Cancer Res
. 2021 Feb;
19(6):1051-1062.
PMID: 33619227
Placental growth factor (PlGF) is a pro-angiogenic, N-glycosylated growth factor, which is secreted under pathologic situations. Here, we investigated the regulation of PlGF in response to ionizing radiation (IR) and...
6.
Grgic I, Tschanz F, Borgeaud N, Gupta A, Clavien P, Guckenberger M, et al.
Int J Radiat Oncol Biol Phys
. 2021 Feb;
110(4):1222-1233.
PMID: 33587991
Purpose: Tumor hypoxia is a major limiting factor for successful radiation therapy outcomes, with hypoxic cells being up to 3-fold more radiation resistant than normoxic cells; tumor hypoxia creates a...
7.
Telarovic I, Krayenbuehl J, Grgic I, Tschanz F, Guckenberger M, Pruschy M, et al.
Phys Med Biol
. 2020 Nov;
65(22):22NT02.
PMID: 33179609
In contrast to conventional radiotherapy, spatiotemporal fractionation (STF) delivers a distinct dose distribution in each fraction. The aim is to increase the therapeutic window by simultaneously achieving partial hypofractionation in...
8.
Deycmar S, Faccin E, Kazimova T, Knobel P, Telarovic I, Tschanz F, et al.
Br J Radiol
. 2019 Nov;
93(1107):20190494.
PMID: 31687835
Clinical parameters and empirical evidence are the primary determinants for current treatment planning in radiation oncology. Personalized medicine in radiation oncology is only at the very beginning to take the...